Financhill
Buy
60

ABT Quote, Financials, Valuation and Earnings

Last price:
$129.85
Seasonality move :
3.81%
Day range:
$129.44 - $132.61
52-week range:
$99.71 - $141.23
Dividend yield:
1.72%
P/E ratio:
17.03x
P/S ratio:
5.43x
P/B ratio:
4.74x
Volume:
6.8M
Avg. volume:
6.5M
1-year change:
7.88%
Market cap:
$225.9B
Revenue:
$42B
EPS (TTM):
$7.65

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ABT
Abbott Laboratories
$11B $1.34 4.19% 52.11% $136.26
BSX
Boston Scientific
$4.4B $0.66 18.49% 103.33% $115.62
DXCM
DexCom
$1.1B $0.50 10.44% -9.12% $101.79
ISRG
Intuitive Surgical
$2.2B $1.79 15.66% 15.62% $632.53
JNJ
Johnson & Johnson
$22.4B $2.01 1.26% 97.05% $169.07
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,006.63
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ABT
Abbott Laboratories
$130.28 $136.26 $225.9B 17.03x $0.59 1.72% 5.43x
BSX
Boston Scientific
$96.42 $115.62 $142.3B 77.14x $0.00 0% 8.56x
DXCM
DexCom
$70.76 $101.79 $27.7B 49.48x $0.00 0% 7.24x
ISRG
Intuitive Surgical
$497.30 $632.53 $177.4B 77.58x $0.00 0% 21.55x
JNJ
Johnson & Johnson
$162.85 $169.07 $392.4B 28.13x $1.24 3.05% 4.45x
LLY
Eli Lilly and
$821.86 $1,006.63 $738.2B 70.18x $1.50 0.66% 16.49x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ABT
Abbott Laboratories
22.86% 0.603 7.72% 1.23x
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
DXCM
DexCom
53.73% 1.028 8.03% 1.23x
ISRG
Intuitive Surgical
-- 1.599 -- 3.08x
JNJ
Johnson & Johnson
33.88% 0.530 10.52% 0.86x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ABT
Abbott Laboratories
$6B $1.9B 24.06% 32.63% 19.74% $2.1B
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
DXCM
DexCom
$655.8M $188.9M 12.52% 26.6% 19.42% $176.8M
ISRG
Intuitive Surgical
$1.6B $734.9M 15.6% 15.6% 30.45% $510.6M
JNJ
Johnson & Johnson
$15.4B $3.8B 13.3% 19.98% 17.87% $4.8B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M

Abbott Laboratories vs. Competitors

  • Which has Higher Returns ABT or BSX?

    Boston Scientific has a net margin of 84.1% compared to Abbott Laboratories's net margin of 12.41%. Abbott Laboratories's return on equity of 32.63% beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
  • What do Analysts Say About ABT or BSX?

    Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.59%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 19.91%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABT
    Abbott Laboratories
    13 6 0
    BSX
    Boston Scientific
    23 4 0
  • Is ABT or BSX More Risky?

    Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

  • Which is a Better Dividend Stock ABT or BSX?

    Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.72%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABT or BSX?

    Abbott Laboratories quarterly revenues are $11B, which are larger than Boston Scientific quarterly revenues of $4.6B. Abbott Laboratories's net income of $9.2B is higher than Boston Scientific's net income of $566M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.03x while Boston Scientific's PE ratio is 77.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.43x versus 8.56x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABT
    Abbott Laboratories
    5.43x 17.03x $11B $9.2B
    BSX
    Boston Scientific
    8.56x 77.14x $4.6B $566M
  • Which has Higher Returns ABT or DXCM?

    DexCom has a net margin of 84.1% compared to Abbott Laboratories's net margin of 13.62%. Abbott Laboratories's return on equity of 32.63% beat DexCom's return on equity of 26.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
    DXCM
    DexCom
    58.9% $0.38 $4.5B
  • What do Analysts Say About ABT or DXCM?

    Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.59%. On the other hand DexCom has an analysts' consensus of $101.79 which suggests that it could grow by 43.85%. Given that DexCom has higher upside potential than Abbott Laboratories, analysts believe DexCom is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABT
    Abbott Laboratories
    13 6 0
    DXCM
    DexCom
    17 3 0
  • Is ABT or DXCM More Risky?

    Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison DexCom has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.527%.

  • Which is a Better Dividend Stock ABT or DXCM?

    Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.72%. DexCom offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. DexCom pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABT or DXCM?

    Abbott Laboratories quarterly revenues are $11B, which are larger than DexCom quarterly revenues of $1.1B. Abbott Laboratories's net income of $9.2B is higher than DexCom's net income of $151.7M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.03x while DexCom's PE ratio is 49.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.43x versus 7.24x for DexCom. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABT
    Abbott Laboratories
    5.43x 17.03x $11B $9.2B
    DXCM
    DexCom
    7.24x 49.48x $1.1B $151.7M
  • Which has Higher Returns ABT or ISRG?

    Intuitive Surgical has a net margin of 84.1% compared to Abbott Laboratories's net margin of 28.41%. Abbott Laboratories's return on equity of 32.63% beat Intuitive Surgical's return on equity of 15.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
    ISRG
    Intuitive Surgical
    68.04% $1.88 $16.5B
  • What do Analysts Say About ABT or ISRG?

    Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.59%. On the other hand Intuitive Surgical has an analysts' consensus of $632.53 which suggests that it could grow by 27.19%. Given that Intuitive Surgical has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABT
    Abbott Laboratories
    13 6 0
    ISRG
    Intuitive Surgical
    14 10 0
  • Is ABT or ISRG More Risky?

    Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.616%.

  • Which is a Better Dividend Stock ABT or ISRG?

    Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.72%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABT or ISRG?

    Abbott Laboratories quarterly revenues are $11B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Abbott Laboratories's net income of $9.2B is higher than Intuitive Surgical's net income of $685.7M. Notably, Abbott Laboratories's price-to-earnings ratio is 17.03x while Intuitive Surgical's PE ratio is 77.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.43x versus 21.55x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABT
    Abbott Laboratories
    5.43x 17.03x $11B $9.2B
    ISRG
    Intuitive Surgical
    21.55x 77.58x $2.4B $685.7M
  • Which has Higher Returns ABT or JNJ?

    Johnson & Johnson has a net margin of 84.1% compared to Abbott Laboratories's net margin of 15.24%. Abbott Laboratories's return on equity of 32.63% beat Johnson & Johnson's return on equity of 19.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
    JNJ
    Johnson & Johnson
    68.35% $1.41 $108.1B
  • What do Analysts Say About ABT or JNJ?

    Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.59%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.82%. Given that Abbott Laboratories has higher upside potential than Johnson & Johnson, analysts believe Abbott Laboratories is more attractive than Johnson & Johnson.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABT
    Abbott Laboratories
    13 6 0
    JNJ
    Johnson & Johnson
    6 13 0
  • Is ABT or JNJ More Risky?

    Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

  • Which is a Better Dividend Stock ABT or JNJ?

    Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.72%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABT or JNJ?

    Abbott Laboratories quarterly revenues are $11B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Abbott Laboratories's net income of $9.2B is higher than Johnson & Johnson's net income of $3.4B. Notably, Abbott Laboratories's price-to-earnings ratio is 17.03x while Johnson & Johnson's PE ratio is 28.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.43x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABT
    Abbott Laboratories
    5.43x 17.03x $11B $9.2B
    JNJ
    Johnson & Johnson
    4.45x 28.13x $22.5B $3.4B
  • Which has Higher Returns ABT or LLY?

    Eli Lilly and has a net margin of 84.1% compared to Abbott Laboratories's net margin of 32.59%. Abbott Laboratories's return on equity of 32.63% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ABT
    Abbott Laboratories
    54.97% $5.27 $62B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About ABT or LLY?

    Abbott Laboratories has a consensus price target of $136.26, signalling upside risk potential of 4.59%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 22.48%. Given that Eli Lilly and has higher upside potential than Abbott Laboratories, analysts believe Eli Lilly and is more attractive than Abbott Laboratories.

    Company Buy Ratings Hold Ratings Sell Ratings
    ABT
    Abbott Laboratories
    13 6 0
    LLY
    Eli Lilly and
    16 4 0
  • Is ABT or LLY More Risky?

    Abbott Laboratories has a beta of 0.696, which suggesting that the stock is 30.418% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock ABT or LLY?

    Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.72%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ABT or LLY?

    Abbott Laboratories quarterly revenues are $11B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Abbott Laboratories's net income of $9.2B is higher than Eli Lilly and's net income of $4.4B. Notably, Abbott Laboratories's price-to-earnings ratio is 17.03x while Eli Lilly and's PE ratio is 70.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.43x versus 16.49x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ABT
    Abbott Laboratories
    5.43x 17.03x $11B $9.2B
    LLY
    Eli Lilly and
    16.49x 70.18x $13.5B $4.4B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Tesla Stock: The Bear Case
Tesla Stock: The Bear Case

The recent stock market drop has been a punishing time…

Is VUG a Good ETF to Buy?
Is VUG a Good ETF to Buy?

For the last few years, earnings growth from the tech…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
50
TREE alert for Mar 13

LendingTree [TREE] is up 1.53% over the past day.

Buy
57
INOD alert for Mar 13

Innodata [INOD] is down 7.4% over the past day.

Sell
40
VIST alert for Mar 13

Vista Energy SAB de CV [VIST] is up 0.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock